Cited by 562Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsMelanoma and MAPK Pathways

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Open access

Lee, Ho-June, Zhuang, Guanglei, Cao, Yi, Du, Pan, Kim, Hyo-Jin, Settleman, Jeff·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.05.019

Open this paper in CoChat — free account Open PDF

Abstract

Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.05.019

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citation
Stat3 as an Oncogene
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Self-citation

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Emerging Biological Principles of Metastasis
Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,191
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 728
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 518
Therapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 503
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer
Castellanos, E. H., Feld, E., & Horn, L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 322
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“…STAT3 plays an important role in the tumor microenvironment, as it modulates antitumor immune response, where it plays dual and complementary roles as an upregulator of tumor immune inhibitors and a suppressor of tumor immune activators (Yu et al., 2007;Marzec et al., 2008; Lee et al., 2014).”
Background
Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis
Gaudino, S. J., & Kumar, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00360 · Cited by 322
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 308
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N. A., Kalyan, A., Matsangou, M., Costa, R. L. B., Carneiro, B. A., Villaflor, V. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 303
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 296
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Büchert, M., Burns, C. J., & Ernst, M. (2015) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 246
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Zhao, C., Li, H., Lin, H.-J. L., Yang, S., Lin, J., & Liang, G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237
A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors
Yan, F., Al‐Kali, A., Zhang, Z. S., Liu, J., Pang, J., Zhao, N., He, C., Litzow, M. R., & Liu, S. (2018) · Cell Research · doi:10.1038/s41422-018-0097-4 · Cited by 235
Do STAT3 inhibitors have potential in the future for cancer therapy?
Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J. Q., Sethi, G., & Goh, B.-C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351941 · Cited by 227
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska‐Owczarek, A., & Stańczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 216
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
CHAIB-OUKADOUR, I., Karachaliou, N., Pilotto, S., Servat, J. C., Cai, X., Li, X., Drozdowskyj, A., Codony, C., Yang, J. E., Hu, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204
Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance
Cui, C., Yang, J., Xiao, L., Liu, D., Fu, L., & Wang, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01180-y · Cited by 205
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Powell, C. E., Gao, Y., Tan, L., Donovan, K. A., Nowak, R. P., Loehr, A., Bahcall, M., Fischer, E. S., Jänne, P. A., George, R. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01655 · Cited by 198
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R. E., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 202
Cytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 199
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Büchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 200
ALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 194
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 178
Thioredoxin Reductase Inhibition for Cancer Therapy
Gencheva, R., & Arnér, E. S. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-102509 · Cited by 181
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 182
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 153
Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development
Sgrignani, J., Garofalo, M., Matkovic, M., Merulla, J., Catapano, C. V., & Cavalli, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061591 · Cited by 168
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Jacobsen, K., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony, C., Codony‐Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 162
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. (2020) · Molecules · doi:10.3390/molecules25204831 · Cited by 165
Surviving apoptosis: life–death signaling in single cells
Flusberg, D. A., & Sorger, P. K. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.003 · Cited by 149
Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis
Wu, P., Wu, D., Zhao, L., Huang, L., Shen, G., Huang, J., & Chai, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7887 · Cited by 149
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
Grabner, B., Schramek, D., Mueller, K. M., Moll, H. P., Svinka, J., Hoffmann, T., Bauer, E., Blaas, L., Hruschka, N., Zboray, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7285 · Cited by 146
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy
Bhat, A. A., Nisar, S., Maacha, S., Carneiro-Lobo, T., Akhtar, S., Siveen, K. S., Wani, N. A., Rizwan, A., Bagga, P., Singh, M. K., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01294-3 · Cited by 145
Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe, J., Liu, J., & Zhang, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.006 · Cited by 144
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
Garg, M., Shanmugam, M. K., Bhardwaj, V., Goel, A., Gupta, R., Sharma, A., Baligar, P., Kumar, A. P., Goh, B. C., Wang, L., et al. (2020) · Medicinal Research Reviews · doi:10.1002/med.21761 · Cited by 143
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance
Poli, V., & Camporeale, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00121 · Cited by 139
Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling
Junk, D. J., Bryson, B. L., Smigiel, J. M., Parameswaran, N., Bartel, C. A., & Jackson, M. W. (2017) · Oncogene · doi:10.1038/onc.2017.33 · Cited by 133
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Kooshkaki, O., Derakhshani, A., Hosseinkhani, N., Torabi, M., Safaei, S., Brunetti, O., Racanelli, V., Silvestris, N., & Baradaran, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124427 · Cited by 135
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 133
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
Tošić, I., & Frank, D. A. (2021) · Neoplasia · doi:10.1016/j.neo.2021.10.003 · Cited by 130
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut · doi:10.1136/gutjnl-2018-317424 · Cited by 130
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 128
Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
Lee, M., Hirpara, J. L., Eu, J. Q., Sethi, G., Wang, L., Goh, B.-C., & Wong, A. L. A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101073 · Cited by 129
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 130
Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance
Hirpara, J. L., Eu, J. Q., Tan, J. K. M., Wong, A. L., Clement, M., Kong, L. R., Ohi, N., Tsunoda, T., Qu, J., Goh, B. C., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101076 · Cited by 126
MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer
Ge, X., Liu, X., Lin, F., Li, P., Liu, K., Geng, R., Dai, C., Lin, Y., Tang, W., Wu, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8228 · Cited by 118
FGF/FGFR signaling pathway involved resistance in various cancer types.
Zhou, Y., Wu, C., Lu, G., Hu, Z., Chen, Q., & Du, X. (2020) · Journal of Cancer · doi:10.7150/jca.40531 · Cited by 117
A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 116
YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation
Sui, H. X., Zhang, L., Gu, K., Chai, N., Ji, Q., Zhou, L., Wang, Y., Ren, J., Yang, L., Zhang, B., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00596-9 · Cited by 114
Targeting STAT3 with silibinin to improve cancer therapeutics
Bosch‐Barrera, J., Queralt, B., & Menéndez, J. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.003 · Cited by 112
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Shien, K., Papadimitrakopoulou, V. A., Ruder, D., Behrens, C., Shen, L., Kalhor, N., Song, J., Lee, J. J., Wang, J., Tang, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0148 · Cited by 109
IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression
Jing, N., Wang, Y., Yang, J. B., & Stark, G. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714102115 · Cited by 113
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
Yadav, P., Ambudkar, S. V., & Prasad, N. R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01626-z · Cited by 109
Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance
Xiao, W., Song, M., Li, W., Huang, J., Yang, G. Y., & Wang, Y. (2021) · Theranostics · doi:10.7150/thno.59342 · Cited by 108
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
Mohrherr, J., Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · Cancers · doi:10.3390/cancers12051107 · Cited by 106
ER Stress Signaling Promotes the Survival of Cancer “Persister Cells” Tolerant to EGFR Tyrosine Kinase Inhibitors
Terai, H., Kitajima, S., Potter, D. S., Matsui, Y., Quiceno, L. G., Chen, T., Kim, T. J., Rusan, M., Thai, T. C., Piccioni, F., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1904 · Cited by 105
Nuclear factor of activated T cells in cancer development and treatment
Shou, J., Jing, J., Xie, J., You, L., Zhao, J., Yao, J., Han, W., & Pan, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.005 · Cited by 106
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
Bottos, A., Gotthardt, D., Gill, J. W., Gattelli, A., Frei, A., Tzankov, A., Sexl, V., Wodnar‐Filipowicz, A., & Hynes, N. E. (2016) · Nature Communications · doi:10.1038/ncomms12258 · Cited by 105
Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress
Maryam, A., Mehmood, T., Zhang, H., Li, Y., Khan, M. N., & Ma, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-06535-y · Cited by 101
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodrı́guez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 104
JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance
Sabaawy, H. E., Ryan, B. M., Khiabanian, H., & Pine, S. R. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab075 · Cited by 106
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 102
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Chemopreventive Potential of Caryophyllane Sesquiterpenes: An Overview of Preliminary Evidence
Sotto, A. D., Mancinelli, R., Gullì, M., Eufemi, M., Mammola, C. L., Mazzanti, G., & Giacomo, S. D. (2020) · Cancers · doi:10.3390/cancers12103034 · Cited by 97
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. I. G., Koch, J. P., Langley, E. J., Singh, S., Kim, P. S., Frampton, G. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2287 · Cited by 96
Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
Brambilla, L., Genini, D., Laurini, E., Merulla, J., Perez, L. H., Fermeglia, M., Carbone, G. M., Pricl, S., & Catapano, C. V. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.012 · Cited by 98
Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway
Yang, L., Lin, S., Kang, Y., Xiang, Y., Xu, L., Li, J., Dai, X., Liang, G., Huang, X., & Zhao, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1015-9 · Cited by 96
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Addressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 95
The emerging role of signal transducer and activator of transcription 3 in cerebral ischemic and hemorrhagic stroke
Liang, Z., Wu, G., Fan, C., Xu, J., Jiang, S., Yan, X., Di, S., Ma, Z., Hu, W., & Yang, Y. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.11.001 · Cited by 92
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
Liu, J., Liu, Y., Meng, L., Liu, K., & Ji, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5722 · Cited by 92
Calcium signaling in cancer progression and therapy
Wu, L., Lian, W., & Zhao, L. (2021) · FEBS Journal · doi:10.1111/febs.16133 · Cited by 91
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
Self-citation
The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression
Sun, C., Li, S., Zhang, F., Zhang, Y., Zuo, Z., Xi, Y., Wang, L., & Li, D. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.96 · Cited by 84
Targeting colon cancer with the novel STAT3 inhibitor bruceantinol
Wei, N., Li, J., Fang, C., Chang, J., Xirou, V., Syrigos, N. K., Marks, B. J., Chu, E., & Schmitz, J. C. (2018) · Oncogene · doi:10.1038/s41388-018-0547-y · Cited by 84
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 86
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 84
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 83
Activation of STAT3 signaling is mediated by TFF1 silencing in gastric neoplasia
Soutto, M., Chen, Z., Bhat, A. A., Wang, L., Zhu, S., Gomaa, A. R., Bates, A. L., Bhat, N. S., Peng, D., Belkhiri, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11011-4 · Cited by 83

Authors: Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J.
Affiliations: Genentech (US)
Corresponding author: Settleman, Jeff
ORCID: Lee, Ho-June
Zhuang, Guanglei
Cao, Yi
Du, Pan
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-08
Volume: 26
Issue: 2
Pages: 207-221
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.05.019
OpenAlex: W2102365935
Cited by: 555
References: 40
Citations by year: 2026: 23 · 2025: 27 · 2024: 36 · 2023: 41 · 2022: 38 · 2021: 61 · 2020: 55 · 2019: 63 · 2018: 46 · 2017: 65 · 2016: 54 · 2015: 42 · 2014: 4
FWCI: 26.52
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: STAT3, drug resistance, oncogene addiction, positive feedback loop, MEK inhibition, JAK inhibition, fibroblast growth factor receptor, EGFR, HER2, anaplastic lymphoma kinase, MET, mutant KRAS, autocrine signaling, combination therapy, tumor regression
MeSH terms: Erlotinib Hydrochloride, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Cell Survival, Humans, Imidazoles, Lung Neoplasms, Mutation, Nitriles, Oncogenes, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Pyrimidines, Quinazolines, Signal Transduction, Interleukin-6, Proto-Oncogene Proteins p21(ras), Mice, SCID, Receptors, Fibroblast Growth Factor, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Kaplan-Meier Estimate, Janus Kinase 1, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks